• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有庞大双取代三唑并嘧啶的铂(II)配合物作为有前景的抗癌剂材料

Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents.

作者信息

Łakomska Iwona, Śmiłowicz Dariusz, Jakubowski Mateusz, Sitkowski Jerzy, Wojtczak Andrzej

机构信息

Faculty of Chemistry, Nicolaus Copernicus University in Toruń, Gagarina 7, 87-100 Toruń, Poland.

Inorganic Chemistry I-Bioinorganic Chemistry, Ruhr-University Bochum, Universitätsstraße 150, 44801 Bochum, Germany.

出版信息

Materials (Basel). 2020 Nov 24;13(23):5312. doi: 10.3390/ma13235312.

DOI:10.3390/ma13235312
PMID:33255252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7727669/
Abstract

Herein, we present dicarboxylate platinum(II) complexes of the general formula [Pt(mal)(DMSO)(L)] and [Pt(CBDC)(DMSO)(L)], where L is dbtp 5,7-diutyl-1,2,4-triazolo[1,5-]pyrimidine) or ibmtp (7-isobutyl-5-methyl-1,2,4- triazolo[1,5-]pyrimidine), as prospective prodrugs. The platinum(II) complexes were synthesized in a one-pot reaction between -[PtCl(DMSO)], silver malonate or silver cyclobutane-1,1-dicarboxylate and triazolopyrimidines. All platinum(II) compounds were characterized by FT-IR, and H, C, N and Pt NMR; and their square planar geometries with one monodentate N(3)-bonded 5,7-disubstituted-1,2,4-triazolo[1,5-]pyrimidine, one S-bonded molecule of dimethyl sulfoxide and one O,O-chelating malonato (, ) or O,O-chelating cyclobutane-1,1-dicarboxylato (, ) was determined. Additionally, [Pt(CBDC)(dbtp)(DMSO)] () exhibited (i) substantial in vitro cytotoxicity against the lung adenocarcinoma epithelial cell line (A549) (IC = 5.00 µM) and the cisplatin-resistant human ductal breast epithelial tumor cell line (T47D) (IC = 6.60 µM); and (ii) definitely exhibited low toxicity against normal murine embryonic fibroblast cells (BALB/3T3).

摘要

在此,我们展示了通式为[Pt(mal)(DMSO)(L)]和[Pt(CBDC)(DMSO)(L)]的二羧酸铂(II)配合物,其中L为dbtp(5,7-二丁基-1,2,4-三唑并[1,5-a]嘧啶)或ibmtp(7-异丁基-5-甲基-1,2,4-三唑并[1,5-a]嘧啶),作为潜在的前药。铂(II)配合物是通过-[PtCl(DMSO)]、丙二酸银或环丁烷-1,1-二羧酸银与三唑并嘧啶在一锅反应中合成的。所有铂(II)化合物均通过傅里叶变换红外光谱、氢、碳、氮和铂核磁共振进行了表征;并确定了它们的平面正方形几何结构,其中有一个单齿N(3)-键合的5,7-二取代-1,2,4-三唑并[1,5-a]嘧啶、一个S-键合的二甲基亚砜分子和一个O,O-螯合的丙二酸根(, )或O,O-螯合的环丁烷-1,1-二羧酸根(, )。此外,[Pt(CBDC)(dbtp)(DMSO)]()表现出:(i) 对肺腺癌上皮细胞系(A549)(IC = 5.00 μM)和顺铂耐药的人乳腺导管上皮肿瘤细胞系(T47D)(IC = 6.60 μM)具有显著的体外细胞毒性;以及 (ii) 对正常小鼠胚胎成纤维细胞(BALB/3T3)表现出低毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/5e31971a6718/materials-13-05312-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/2d79c18879c5/materials-13-05312-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/4cb2621d13a8/materials-13-05312-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/63591c2b459c/materials-13-05312-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/00da58f2f874/materials-13-05312-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/5e31971a6718/materials-13-05312-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/2d79c18879c5/materials-13-05312-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/4cb2621d13a8/materials-13-05312-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/63591c2b459c/materials-13-05312-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/00da58f2f874/materials-13-05312-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de5/7727669/5e31971a6718/materials-13-05312-g005.jpg

相似文献

1
Platinum(II) Complexes with Bulky Disubstitute Triazolopyrimidines as Promising Materials for Anticancer Agents.具有庞大双取代三唑并嘧啶的铂(II)配合物作为有前景的抗癌剂材料
Materials (Basel). 2020 Nov 24;13(23):5312. doi: 10.3390/ma13235312.
2
Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth.含1,2,4-三唑并[1,5-a]嘧啶衍生物的细胞毒性丙二酸铂(II)配合物:结构表征及抑制肿瘤细胞生长的机制
J Inorg Biochem. 2014 Dec;141:188-197. doi: 10.1016/j.jinorgbio.2014.08.005. Epub 2014 Aug 19.
3
Rational design of dicarboxylato platinum(II) complexes with purine-mimetic ligands as novel anticancer agents.以嘌呤模拟配体为新型抗癌剂的二羧基铂(II)配合物的合理设计。
J Inorg Biochem. 2017 Jul;172:34-45. doi: 10.1016/j.jinorgbio.2017.04.003. Epub 2017 Apr 4.
4
Factors Affecting the Stability of Platinum(II) Complexes with 1,2,4-Triazolo[1,5-]pyrimidine Derivatives and Tetrahydrothiophene-1-Oxide or Diphenyl Sulfoxide.影响 1,2,4-三唑并[1,5-a]嘧啶衍生物与四氢噻吩-1-氧化物或二苯砜配合物稳定性的因素。
Int J Mol Sci. 2022 Mar 26;23(7):3656. doi: 10.3390/ijms23073656.
5
Structure-cytotoxicity relationship for different types of mononuclear platinum(II) complexes with 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine.不同类型单核铂(II)配合物与 5,7-二叔丁基-1,2,4-三唑并[1,5-a]嘧啶的结构-细胞毒性关系。
J Inorg Biochem. 2012 Oct;115:100-5. doi: 10.1016/j.jinorgbio.2012.05.005. Epub 2012 May 23.
6
Multinuclear NMR spectroscopy and antitumor activity of novel platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo[1,5-a]pyrimidines.新型含5,7-二取代-1,2,4-三唑并[1,5-a]嘧啶的铂(II)配合物的多核核磁共振光谱及抗肿瘤活性
J Inorg Biochem. 2004 Jan;98(1):167-72. doi: 10.1016/j.jinorgbio.2003.09.001.
7
First dinuclear rhodium(II) complexes with triazolopyrimidines and the prospect of their potential biological use.首例双核铑(II)配合物与三唑并嘧啶,并展望其潜在的生物应用。
J Inorg Biochem. 2020 Sep;210:111072. doi: 10.1016/j.jinorgbio.2020.111072. Epub 2020 Mar 23.
8
Platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo [1,5-a]pyrimidines: spectroscopical characterization and cytotoxic activity in vitro.含 5,7-二取代-1,2,4-三唑并[1,5-a]嘧啶的铂(II)配合物:光谱学表征和体外细胞毒性活性。
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jun;91:126-9. doi: 10.1016/j.saa.2012.01.050. Epub 2012 Jan 30.
9
Nanoencapsulation of a ruthenium(ii) complex with triazolopyrimidine in liposomes as a tool for improving its anticancer activity against melanoma cell lines.脂质体中三唑并嘧啶钌配合物的纳米封装作为提高其对黑素瘤细胞系抗癌活性的工具。
Dalton Trans. 2020 Jan 28;49(4):1207-1219. doi: 10.1039/c9dt03464a. Epub 2020 Jan 6.
10
Palladium(II) and platinum(II) organometallic complexes with 4,7-dihydro-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine. Antitumor activity of the platinum compounds.钯(II)和铂(II)与4,7-二氢-5-甲基-7-氧代[1,2,4]三唑并[1,5-a]嘧啶形成的有机金属配合物。铂化合物的抗肿瘤活性。
Inorg Chem. 2008 Jun 2;47(11):4490-505. doi: 10.1021/ic701873b. Epub 2008 Apr 30.

引用本文的文献

1
Oxidative Aromatization of 4,7-Dihydro-6-nitroazolo[1,5-a]pyrimidines: Synthetic Possibilities and Limitations, Mechanism of Destruction, and the Theoretical and Experimental Substantiation.4,7-二氢-6-硝基氮杂并[1,5-a]嘧啶的氧化芳构化:合成的可能性和限制、破坏机制以及理论和实验的证实。
Molecules. 2021 Aug 4;26(16):4719. doi: 10.3390/molecules26164719.

本文引用的文献

1
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?迈向多靶点铂类和钌类药物——癌症药物治疗方案的新模式?
Chem Rev. 2019 Jan 23;119(2):1058-1137. doi: 10.1021/acs.chemrev.8b00271. Epub 2019 Jan 14.
2
Cytotoxic malonate platinum(II) complexes with 1,2,4-triazolo[1,5-a]pyrimidine derivatives: structural characterization and mechanism of the suppression of tumor cell growth.含1,2,4-三唑并[1,5-a]嘧啶衍生物的细胞毒性丙二酸铂(II)配合物:结构表征及抑制肿瘤细胞生长的机制
J Inorg Biochem. 2014 Dec;141:188-197. doi: 10.1016/j.jinorgbio.2014.08.005. Epub 2014 Aug 19.
3
Synthesis, anticancer activity and toxicity of a water-soluble 4S,5S-derivative of heptaplatin, cis-{Pt(II)[(4S,5S)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]·(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}.
J Inorg Biochem. 2014 Nov;140:126-30. doi: 10.1016/j.jinorgbio.2014.07.013. Epub 2014 Jul 22.
4
Antitumor platinum(II) complexes of N-monoalkyl 1R,2R-diamino-cyclohexanes with 3-(nitrooxy)cyclobutane-1,1-dicarboxylate as a leaving group.以3-(硝基氧基)环丁烷-1,1-二羧酸酯作为离去基团的N-单烷基-1R,2R-二氨基环己烷的抗肿瘤铂(II)配合物。
Eur J Med Chem. 2014 Oct 6;85:408-17. doi: 10.1016/j.ejmech.2014.08.007. Epub 2014 Aug 5.
5
Bispidine analogues of cisplatin, carboplatin, and oxaliplatin. synthesis, structures, and cytotoxicity.
Inorg Chem. 2014 Apr 7;53(7):3371-84. doi: 10.1021/ic402737f. Epub 2014 Mar 25.
6
Platinum(II) complexes with N-monoalkyl 1R,2R-diaminocyclohexane derivatives as carrier ligands and 3-hydroxycyclobutane-1,1-dicarboxylate as a leaving group: potent cytotoxicity and DNA binding ability.含 N-单烷基 1R,2R-二氨基环己烷衍生物作为载体配体和 3-羟基环丁烷-1,1-二羧酸酯作为离去基团的铂(II)配合物:具有很强的细胞毒性和 DNA 结合能力。
Eur J Med Chem. 2013 Nov;69:842-7. doi: 10.1016/j.ejmech.2013.07.004. Epub 2013 Sep 27.
7
Nanocarriers for delivery of platinum anticancer drugs.纳米载体用于递送铂类抗癌药物。
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1667-85. doi: 10.1016/j.addr.2013.09.014. Epub 2013 Oct 8.
8
Anticancer potency of platinum(II) complexes containing both chloride anion and chelated carboxylate as leaving groups.含氯离子和螯合羧酸盐作为离去基团的铂(II)配合物的抗癌活性。
Inorg Chem. 2013 Jul 15;52(14):8163-70. doi: 10.1021/ic400907t. Epub 2013 Jun 28.
9
Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties.纳米颗粒包裹米铂及其对体内性质的影响。
ACS Nano. 2013 Jul 23;7(7):5675-83. doi: 10.1021/nn401905g. Epub 2013 May 22.
10
Structure-cytotoxicity relationship for different types of mononuclear platinum(II) complexes with 5,7-ditertbutyl-1,2,4-triazolo[1,5-a]pyrimidine.不同类型单核铂(II)配合物与 5,7-二叔丁基-1,2,4-三唑并[1,5-a]嘧啶的结构-细胞毒性关系。
J Inorg Biochem. 2012 Oct;115:100-5. doi: 10.1016/j.jinorgbio.2012.05.005. Epub 2012 May 23.